Literature DB >> 7849708

9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene.

C Carbonara1, L Longa, E Grosso, C Borrone, M G Garrè, M Brisigotti, N Migone.   

Abstract

Tuberous sclerosis is an autosomal dominant disease whose characteristic feature is the development of multiple hamartomas in a variety of organs and tissues. Two major loci have been identified so far: TSC1 on chromosome 9q34 and TSC2 on chromosome 16p13.3. Loss of heterozygosity at 16p13.3-associated markers has been recently observed in hamartomatous lesions of some tuberous sclerosis patients. Here we report the first evidence of loss of heterozygosity at the TSC1 critical region in a giant cell astrocytoma of a familial tuberous sclerosis case. Segregation analysis showed that the 9q34 haplotype lost carried the putative normal TSC1 gene. These data support the hypothesis of both a germline and somatic loss-of-function mutation for the development of tuberous sclerosis hamartomas and suggest a tumor-suppressor-like activity also for the TSC1 gene product. Finally, the possible significance of a second small region of loss of heterozygosity at 9p21, found in the same astrocytoma, is discussed.

Entities:  

Mesh:

Year:  1994        PMID: 7849708     DOI: 10.1093/hmg/3.10.1829

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  26 in total

1.  A defect in protein farnesylation suppresses a loss of Schizosaccharomyces pombe tsc2+, a homolog of the human gene predisposing to tuberous sclerosis complex.

Authors:  Yukiko Nakase; Keiko Fukuda; Yuji Chikashige; Chihiro Tsutsumi; Daisuke Morita; Shinpei Kawamoto; Mari Ohnuki; Yasushi Hiraoka; Tomohiro Matsumoto
Journal:  Genetics       Date:  2006-04-19       Impact factor: 4.562

Review 2.  Tuberous sclerosis complex: new insights into clinical and therapeutic approach.

Authors:  Angela Volpi; Gabriele Sala; Elena Lesma; Francesca Labriola; Marco Righetti; Rosa Maria Alfano; Mario Cozzolino
Journal:  J Nephrol       Date:  2018-11-07       Impact factor: 3.902

Review 3.  Neurological manifestations of tuberous sclerosis complex.

Authors:  P Curatolo
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

4.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Authors:  T Carsillo; A Astrinidis; E P Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

5.  Mutations in the TSC1 gene account for a minority of patients with tuberous sclerosis.

Authors:  J B Ali; T Sepp; S Ward; A J Green; J R Yates
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

6.  Expression and differential splicing of the mouse TSC2 homolog.

Authors:  P G Olsson; J N Schofield; Y H Edwards; A M Frischauf
Journal:  Mamm Genome       Date:  1996-03       Impact factor: 2.957

7.  Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions.

Authors:  Y Niida; A O Stemmer-Rachamimov; M Logrip; D Tapon; R Perez; D J Kwiatkowski; K Sims; M MacCollin; D N Louis; V Ramesh
Journal:  Am J Hum Genet       Date:  2001-07-20       Impact factor: 11.025

Review 8.  Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

9.  Role of the Tsc1-Tsc2 complex in signaling and transport across the cell membrane in the fission yeast Schizosaccharomyces pombe.

Authors:  Sanae Matsumoto; Amitabha Bandyopadhyay; David J Kwiatkowski; Umadas Maitra; Tomohiro Matsumoto
Journal:  Genetics       Date:  2002-07       Impact factor: 4.562

10.  Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

Authors:  Philippe P Roux; Bryan A Ballif; Rana Anjum; Steven P Gygi; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.